| Literature DB >> 24391592 |
Abhishek Garg1, Kartik Mohanram2, Alessandro Di Cara3, Gwendoline Degueurce4, Mark Ibberson1, Julien Dorier1, Ioannis Xenarios5.
Abstract
In the last few decades, technological and experimental advancements have enabled a more precise understanding of the mode of action of drugs with respect to human cell signaling pathways and have positively influenced the design of new drug compounds. However, as the design of compounds has become increasingly target-specific, the overall effects of a drug on adjacent cellular signaling pathways remain difficult to predict because of the complexity of the interactions involved. Off-target effects of drugs are known to influence their efficacy and safety. Similarly, drugs which are more target-specific also suffer from lack of efficacy because their scope might be too limited in the context of cellular signaling. Even in situations where the signaling pathways targeted by a drug are known, the presence of point mutations in some of the components of the pathways can render a therapy ineffective in a considerable target subpopulation. Some of these issues can be addressed by predicting Minimal Intervention Sets (MIS) of elements of the signaling pathways that when perturbed give rise to a pre-defined cellular phenotype. These minimal gene perturbation sets can then be further used to screen a library of drug compounds in order to discover effective drug therapies. This manuscript describes algorithms that can be used to discover MIS in a gene regulatory network that can lead to a defined cellular phenotype. Algorithms are implemented in our Boolean modeling toolbox, GenYsis. The software binaries of GenYsis are available for download from http://www.vital-it.ch/software/genYsis/.Entities:
Keywords: GRN; MIS; T-Helper; algorithms; boolean modeling; cancer pathways; miRNA; qualitative modeling
Year: 2013 PMID: 24391592 PMCID: PMC3867968 DOI: 10.3389/fphys.2013.00361
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.566
Figure 1(A) A toy GRN representing interactions between a set of genes/proteins. Arrow-headed edges represent activation and circle-headed edges represent inhibiting interactions. (B) MIS patters to push the systems into a steady state where T = 1. For every MIS vector there is at least one mutations that has to be present. The polarity of these mandatory mutations are indicated by red (knock-out) or blue (over-express) colors. In addition, compatible off-target mutations and their polarities (over-expression or knock-out) are also listed for every MIS vector. Genes correponding to white color in an MIS vector indicate the mutations in these genes have no effect on the corresponding MIS vector. Genes correponding to gray color in an MIS vector should not be perturbed in any polarity (either by knock-out or over-expression). Else the corresponding MIS vector may not be able to generate the desired steady state.
Figure 5Algorithms for computing the MIS patterns given a Boolean GRN and the profile of desired steady states.
Figure 6Algorithms for merging MIS patterns.
Figure 2(A) Unrolled GRN when the node T has a fixed polarity in steady states. The labels 0 and 1 next to node labels represent polarity propagated from the root node T = 1 to the leaf nodes in the unrolled networks. (B) Propagation of MIS patterns through an AND gate. (C) Propagation of MIS patterns through an OR gate.
Figure 3(A) T-Helper Gene Regulatory Network. Green arrow-headed edges represent activating interactions and red colored round-headed edges represent inhibiting edges. (B) Profile of three steady states present in T-Helper GRN representing Th0, Th1, and Th2 cellular phenotypes. (C) MIS patterns indicating gene-perturbations in-order to generate Th1 steady states. These MIS patterns have no pre-requirement on the initial state of the network. (D) MIS patterns to push the system into Th1 phenotype when the system is initially in Th0 steady state.
Figure 4(A) GRN representing interactions among some proteins known to play a crucial role in maintaining a balance between apoptosis and cellular growth in cancer signaling pathways. (B) Distribution of growth and apoptosis signals in the steady states of the wild-type GRN [labeled (wt)], or in the presence of p53 or TSC knock-out mutations (labeled p53- and TSC-), and of the GRN where the knock-out affects of drugs targeting mTORC1 (labeled mTORC1-) and PI3K (labeled PI3K-) are modeled. (C) MIS patterns indicating gene-perturbations necessary for in-order to push the system into the state correponding to constitutive high-growth and low-apoptosis signals.